Investigational new drugs for brain cancer.
Investigational new drugs for brain cancer.
复制标题
DOI：
10.1080/13543784.2016.1182497
复制
发表时间：
2016-08
影响因子：
6.1
通讯作者：
Laterra J
中科院分区：
文献类型：
--
作者：
Staedtke V;Bai RY;Laterra J
尽管护理标准有了实质性的改善，但由于独特的治疗限制、高复发率和复发后缺乏有效治疗，最常见的侵袭性儿科和成人高级别胶质瘤（HGG）具有一致的致命性诊断。我们对病理生理学、遗传学和表观遗传学以及胶质瘤形成过程中免疫监视机制的理解的最新进展创造了新的知识，以设计更有效和靶向的治疗方法来改善患者的预后。在这篇综述中，作者讨论了神经胶质瘤中发现的关键遗传、表观遗传和免疫学畸变，这些畸变在目前和未来的治疗发展中显得合理和有希望。本文综述了肿瘤靶向药物治疗、代谢靶向、表观遗传调控和免疫治疗等方面的最新进展，并对未来的发展方向提出了建议。此外，他们强调了与临床开发相关的当代问题，例如临床试验和毒性的挑战。致力于了解神经胶质瘤的过程已经创建了一个畸变的目录，描述了这种疾病的多种机制，其中许多适合于治疗抑制，目前正在临床试验中进行测试。因此，未来的治疗努力将采用多种治疗方式，这些治疗方式针对患者个体肿瘤个性化的不同肿瘤特征。
Despite substantial improvements in standards of care, the most common aggressive pediatric and adult high-grade gliomas (HGG) carry uniformly fatal diagnoses due to unique treatment limitations, high recurrence rates and the absence of effective treatments following recurrence. Recent advancements in our understanding of the pathophysiology, genetics and epigenetics as well as mechanisms of immune surveillance during gliomagenesis have created new knowledge to design more effective and target-directed therapies to improve patient outcomes. In this review, the authors discuss the critical genetic, epigenetic and immunologic aberrations found in gliomas that appear rational and promising for therapeutic developments in the presence and future. The current state of the latest therapeutic developments including tumor-specific targeted drug therapies, metabolic targeting, epigenetic modulation and immunotherapy are summarized and suggestions for future directions are offered. Furthermore, they highlight contemporary issues related to the clinical development, such as challenges in clinical trials and toxicities. The commitment to understanding the process of gliomagenesis has created a catalogue of aberrations that depict multiple mechanisms underlying this disease, many of which are suitable to therapeutic inhibition and are currently tested in clinical trials. Thus, future treatment endeavors will employ multiple treatment modalities that target disparate tumor characteristics personalized to the patient’s individual tumor.
登录
查看更多内容
DOI：
10.4137/cmo.s7232
发表时间：
2011
期刊：
Clinical Medicine Insights. Oncology
影响因子：
--
作者：
Chamberlain MC
通讯作者：
Chamberlain MC
DOI：
10.1016/j.ijrobp.2012.10.008
发表时间：
2013-04-01
影响因子：
7
作者：
Chakravarti, Arnab;Wang, Meihua;Robins, H. Ian;Lautenschlaeger, Tim;Curran, Walter J.;Brachman, David G.;Schultz, Christopher J.;Choucair, Ali;Dolled-Filhart, Marisa;Christiansen, Jason;Gustavson, Mark;Molinaro, Annette;Mischel, Paul;Dicker, Adam P.;Bredel, Markus;Mehta, Minesh
通讯作者：
Mehta, Minesh
雷帕霉素在I期试验中针对复发性PTEN缺陷型胶质母细胞瘤患者的抗肿瘤活性。
影响因子：
15.8
作者：
Cloughesy, Tim F.;Yoshimoto, Koji;Nghiemphu, Phioanh;Brown, Kevin;Dang, Julie;Zhu, Shaojun;Hsueh, Teli;Chen, Yinan;Wang, Wei;Youngkin, David;Liau, Linda;Martin, Neil;Becker, Don;Bergsneider, Marvin;Lai, Albert;Green, Richard;Oglesby, Tom;Koleto, Michael;Trent, Jeff;Horvath, Steve;Mischel, Paul S.;Mellinghoff, Ingo K.;Sawyers, Charles L.
通讯作者：
Sawyers, Charles L.
对胶质母细胞瘤的热休克蛋白疫苗：从长凳到床边。
影响因子：
3.9
作者：
Ampie L;Choy W;Lamano JB;Fakurnejad S;Bloch O;Parsa AT
通讯作者：
Parsa AT
影响因子：
--
作者：
Borodovsky A;Salmasi V;Turcan S;Fabius AW;Baia GS;Eberhart CG;Weingart JD;Gallia GL;Baylin SB;Chan TA;Riggins GJ
通讯作者：
Riggins GJ